Trillium Therapeutics Inc (TRIL.OQ)

Tue, Apr 10 2018

BRIEF-Trillium Therapeutics Provides Update On Its Clinical Programs

* TRILLIUM THERAPEUTICS PROVIDES UPDATE ON ITS TTI-621 AND TTI-622 CLINICAL PROGRAMS

BRIEF-Trillium Therapeutics' TTI-621 Receives Orphan Drug Designation For Treatment Of Cutaneous T-Cell Lymphoma

* TRILLIUM THERAPEUTICS' TTI-621 RECEIVES ORPHAN DRUG DESIGNATION FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA Source text for Eikon: Further company coverage:

BRIEF-Trillium Therapeutics Reports Annual 2017 Financial And Operating Results

* TRILLIUM THERAPEUTICS REPORTS ANNUAL 2017 FINANCIAL AND OPERATING RESULTS

BRIEF-Trillium Therapeutics Inc Files For Mixed Shelf Of Upto $150 Mln

* TRILLIUM THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text : http://bit.ly/2jZxGi0 Further company coverage:

BRIEF-Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics

* MATRIX CAPITAL MANAGEMENT COMPANY LP REPORTS A 16.5 PCT PASSIVE STAKE IN TRILLIUM THERAPEUTICS INC AS OF NOV 30 - SEC FILING Source text: (http://bit.ly/2yOHuTW) Further company coverage:

BRIEF-Trillium announces private placement to fund development of cancer drugs

* Trillium Therapeutics - ‍entered into subscription agreements for sale of 1.95 million shares & 400,000 Series II non-voting convertible first preferred shares